Abstracts tagged "Crohn’s Disease"

Abstract Number: 610 • 2014 ACR/ARHP Annual Meeting
Functional Implications of the Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) Association with Ankylosing Spondylitis and Crohn’s Disease: Impact on the Unfolded Protein Response
Zhenbo Zhang¹, Francesco Ciccia², Kirby Yee³, Giuliana Guggino², Hasan Abdullah⁴, Ricardo Alessandro⁵, Stefania Raimondo⁵, Giovanni Triolo⁵ and Nigil Haroon^1,6,7, ¹Toronto Western Research Institute, Toronto, ON, Canada, ²Rheumatology Unit, University of Palermo, Palermo, Italy, ³McMaster University, Hamilton, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵University of Palermo, Palermo, Italy, ⁶Rheumatology, University Health Network, Toronto, ON, Canada, ⁷Medicine, Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) has found to be associated with AS and Crohn’s Disease (CD). The functional implications of this association have not…
Abstract Number: 2695 • 2013 ACR/ARHP Annual Meeting
Host Genetic Background Disrupts The Relationship Between Microbiota and Gut Mucosal Tolerance Leading To Spondyloarthritis and Ileitis After a Dectin-1 Trigger
Linda Rehaume¹, Stanislas Mondot², Daniel Aguirre de Cárcer², Jared Velasco¹, Helen Benham¹, Sumaira Hasnain³, Jaclyn Bowman¹, Merja Ruutu¹, Philip Hansbro⁴, Michael McGuckin³, Mark Morrison² and Ranjeny Thomas¹, ¹University of Queensland Diamantina Institute, Brisbane, Australia, ²CSIRO Livestock Industries, Brisbane, Australia, ³Mater Medical Research Institute, Brisbane, Australia, ⁴Center for Asthma and Respiratory Disease and Hunter Medical Research Institute, Newcastle, Australia
Background/Purpose: Chronic inflammatory diseases known as spondyloarthropathies (SpA) including ankylosing spondylitis, psoriatic arthritis, reactive arthritis, and arthritis associated with inflammatory bowel disease, collectively affect 3%…
Abstract Number: 433 • 2013 ACR/ARHP Annual Meeting
Retrospective Analysis Of Certolizumab Pegol Use During Pregnancy: Update Of Impact On Birth Outcomes
Megan E. B. Clowse¹, Douglas C. Wolf², Frauke Förger³, John J. Cush⁴, Christian Stach⁵, Gordana Kosutic⁶, Susan Williams⁶, Chidi Maduka⁶ and Uma Mahadevan⁷, ¹Rheumatology, Duke University Medical Center, Durham, NC, ²Atlanta Gastroenterology Associates, Atlanta, GA, ³Department of Rheumatology and Clinical Immunology and Allergology, Inselspital, University of Bern, Bern, Switzerland, ⁴Baylor Research Institute and Baylor University Medical Center, Dallas, TX, ⁵UCB Pharma, Monheim, Germany, ⁶UCB Pharma, Raleigh, NC, ⁷UCSF Medical Center, San Francisco, CA
Background/Purpose: Certolizumab pegol (CZP) is a PEGylated Fc-free anti-TNF approved in 45 countries for the treatment of rheumatoid arthritis (RA) and/or Crohn's disease (CD). An…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].